PATENT CLAIM ANALYSIS

Application Number: 15898258
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2019-02
Patent Classification: ["514", "263400"]

Abstract:
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

Claim (Index 6):
The compound of  claim 5 , wherein:\n R 1  is independently C 1-6  alkyl, C(\u2550O)R a , \u2014C(\u2550O)OR a , \u2014S(O) 2 (CH 3 ), or \u2014C(\u2550O)N(CH 3 ) 2 ; R 2  is independently H, CH 3  or CH 2 CH 3 ; R 3  is H or CH 3 ; R 5  is independently CH 3 , cyclopentyl, cyclopentenyl, phenyl, pyrazol-1-yl, or pyrazol-3-yl; and R a  is CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , C(CH 3 ) 3 , or cyclopropyl.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 88.0
- Lexical Diversity: 1.95588
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16093990', '16094000', '12813148', '15016841', '14982131']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.780755861501021
- 35 USC 102 Novelty (BERT): 0.5192623171008321
- Combined Prediction Score: 0.7546065070610022
- Mean Citation Score: 263.79211200000003
- Max Citation Score: 286.65015
- Similarity Product: 177.28088278763298

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test